resources

Press Release

July 17th, 2024

CytoReason Secures $80M from OurCrowd, NVIDIA, Pfizer, and Thermo Fisher Scientific to Scale Its AI Disease Models and Establish US Hub in Cambridge, Massachusetts

Press Release

May 15th, 2024

CytoReason and the Crohn’s & Colitis Foundation Forge Groundbreaking Data Collaboration to Advance IBD Research

Press Release

January 23rd, 2023

CytoReason to License Its IBD Disease Model to Sanofi in Expanded Multiyear, Multimillion Dollar Deal

Press Release

November 29th, 2022

Poolbeg Pharma reaches R&D milestone as partner CytoReason completes AI influenza disease model

Press Release

September 20th, 2022

CytoReason Announces Expanded Collaboration Deal with Pfizer to Deliver AI for Drug Discovery and Development

Press Release

April 12th, 2022

CytoReason Expands Its Reach in Asia, Forging Commercial Alliance with Helixrus to Leverage Machine Learning in Drug Development for Korean Drugmakers

Press Release

February 10th, 2022

CytoReason and Pfizer Extend Collaboration to Leverage Machine Learning in Drug Development

Press Release

September 30th, 2021

Cytoreason and Summit Pharmaceuticals International forge commercial alliance to bring CytoReason’s machine learning model of the immune system for drug discovery & development to Japanese drug makers

Press Release

June 17th, 2021

CytoReason Collaborates with Sanofi, Using its AI Technology to Gain Better Understanding of Disease Mechanisms

Bring your data to life